Tropifexor (LJN452) in NASH
FLIGHT-FXR Study: Tropifexor (LJN452)
in NASH: phase 2b (interim results)
Sanyal AJ, AASLD 2018, Abs. LB-23
Design
![](/nash/AL_Tropifexor_Abs_LB23/Diapositive1.jpg)
Endpoints
- Safety, liver fat content (MRI-PDFF), liver biochemistry
Results (parts A and B)
![](/nash/AL_Tropifexor_Abs_LB23/Diapositive2.jpg)
Geometric mean % change from baseline in ALT (IU/L), 95% CI – Parts A and B
![](/nash/AL_Tropifexor_Abs_LB23/Diapositive3.jpg)
Geometric mean % change from baseline in GGT (IU/L), 95% CI – Parts A and B
![](/nash/AL_Tropifexor_Abs_LB23/Diapositive4.jpg)
Safety
- Comparable rates of adverse events, including pruritus, for Tropifexor and placebo
- Mild dose response increase of LDL and decrease of HDL, unchanged triglycerides